Summary:
A phase I randomized, double-blind, placebo controlled trial to investigate the efficacy of chloroquine to decrease T-cell activation and decrease viral load in early HIV.
Scientific Rationale:
Chloroquine has in vivo direct anti-HIV effects and an anti-inflammatory effect. These properties may be beneficial in reducing viral burden and immune activation therefore delaying HIV disease progression.
Sample Size: 25
Length of Study: 8 weeks, \[enrollment + 2 follow up visits\].
Intervention:
* Arm 1a: Chloroquine 250mg orally once daily for 8 weeks.
* Arm 1b: Chloroquine 500mg orally once daily for 8 weeks.
* Arm 2: Placebo once daily for 8 weeks.
Measurements:
* Blood draws at weeks: 0, 4, and 8 weeks.
* CD4, viral load measurements will be communicated to the referring provider (with subject consent).
